Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Lambert, Tim ^a,b   Emmerson, Brett ^c   Hustig, Harry ^d   Resseler, Sophie ^e   Jacobs, An ^f   Butcher, Belinda ^f,g  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e Life Science Services Biometrics   (Belgium)

^f JANSSEN RESEARCH FOUNDATION   (Belgium)

^g WriteSource Medical Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE; ZUCLOPENTHIXOL; NEUROLEPTIC AGENT; LONG ACTING DRUG;

ADULT; AGGRESSION; AKATHISIA; ARTICLE; AUSTRALIA; CLINICAL GLOBAL IMPRESSION SCALE; DEATH; DISEASE REGISTRY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTRONIC MEDICAL RECORD; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMONIA; PRESCRIPTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; ADOLESCENT; CHRONIC DISEASE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; HOSPITALIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; REGISTER; STATISTICS; TREATMENT FAILURE; AUSTRALIAN; GLOBAL ASSESSMENT OF FUNCTIONING; LONG TERM CARE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REGISTRIES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 84858734196     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-25     Document Type: Article

References (24)

1. Separation, psychiatric care day and patient day statistics for separations with specialised psychiatric care by principal diagnosis in ICD-10-AM, Australia, 1998-99 to 2005-06. Date accessed 7 March 2011., http://www.aihw.gov.au/principal-diagnosis-data-cubes/
2. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997, 28(2-3):199-206. 10.1016/S0920-9964(97)00131-X, 9468354.
3. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23(10):2305-2312. 10.1185/030079907X226050, 17697454.
4. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995, 40(3 Suppl 1):S5-S11.
5. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005, 39(1-2):1-30.
6. National Institute for Health and Clinical Excellence Guidance on the use of newer (atypical) antipsychotic drugs for the treatmetn of schizophrenia (TA43) 2002, London: National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence.
7. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, Villalobos Vega JC, Cuellar JA, de Castro FJ, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009, 24(5):287-296. 10.1016/j.eurpsy.2008.12.002, 19195847.
8. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) 2000, Washington, DC: American Psychiatric Association, American Psychiatric Association.
9. Janssen-Cilag Pty Ltd Risperdal Consta (risperidone) intramuscular injection product information. Therapeutics Goods Administration approval of last amendment 28 April 2010 2009, Janssen-Cilag Pty Ltd., https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03675-3
10. Guy W. ECDEU Assessment manual for psychopharmacology 1976, Rockville, MD: National Institute of Mental Health.
11. Gureje O, Herrman H, Harvey C, Morgan V, Jablensky A. The Australian National Survey of Psychotic Disorders: profile of psychosocial disability and its risk factors. Psychol Med 2002, 32(4):639-647.
12. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, Wright P, Knapp M. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003, 107(3):222-232. 10.1034/j.1600-0447.2003.00064.x, 12580830.
13. Viner MW, Matuszak JM, Knight LJ. Initial dosing strategies for long-acting injectable risperidone. J Clin Psychiatry 2006, 67(8):1310-1311. 10.4088/JCP.v67n0821e, 16965217.
14. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31(10):2318-2325.
15. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003, 160(6):1125-1132. 10.1176/appi.ajp.160.6.1125, 12777271.
16. Schwartz RC. Concurrent validity of the Global Assessment of Functioning Scale for clients with schizophrenia. Psychol Rep 2007, 100(2):571-574. 10.2466/pr0.100.2.571-574, 17564234.
17. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67(3):453-460. 10.4088/JCP.v67n0317, 16649833.
18. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005, 3:21. 10.1186/1741-7015-3-21, 1327673, 16375765.
19. Liu-Seifert H, Ascher-Svanum H, Osuntokun O, Jen KY, Gomez JC. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BMC Psychiatry 2011, 11:87. 10.1186/1471-244X-11-87, 3125242, 21586165.
20. Lambert T, Kelly DL, Alcock S, Conley RR. Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. J Clin Psychopharmacol 2004, 24(1):91-93. 10.1097/01.jcp.0000106224.36344.11, 14709954.
21. Olivares JM, Rodriguez-Martinez A, Buron JA, Alonso-Escolano D, Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008, 6(1):41-53. 10.2165/00148365-200806010-00004, 18774869.
22. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000, 321(7273):1371-1376. 10.1136/bmj.321.7273.1371, 27538, 11099280.
23. Martin JL, Perez V, Sacristan M, Rodriguez-Artalejo F, Martinez C, Alvarez E. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry 2006, 21(1):11-20. 10.1016/j.eurpsy.2005.09.009, 16380237.
24. Schmauss M, Sacchetti E, Kahn JP, Medori R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 2007, 22(2):85-92. 10.1097/YIC.0b013e3280119ddb, 17293708.